世界病毒学杂志(英文版)最新文献

{"title":"Human immunodeficiency virus vaccines: Advances, challenges and future perspectives.","authors":"Subashchandrabose Varatharajan, Sathiamoorthy Krishnasai, Chandrashekaran Girish","doi":"10.5501/wjv.v15.i1.116055","DOIUrl":"10.5501/wjv.v15.i1.116055","url":null,"abstract":"<p><p>In the past 40 years, much effort has been made to develop a vaccine that can prevent human immunodeficiency virus (HIV) infection. But till today, this continues to be an unresolved challenge. The main obstacle in developing a vaccine is the ability of the virus to mutate at a swift rate, thereby evading the immune system. This has dramatically slowed the progress in the development of an HIV vaccine. Previous studies, like RV144, have demonstrated limited protection. Current trials, such as Imbokodo and Mosaico, have shown that the vaccines used were safe but did not demonstrate efficacy against the HIV-1 virus. With the advent of mRNA vaccines and broad neutralising antibodies, research has shown some progress in developing a promising candidate vaccine. Recently, the use of mosaic antigens and germline-targeting techniques has shed light on the development of a promising candidate vaccine. These techniques educate the immune system slowly. This review tracks the progress of HIV vaccine development to date and examines the most promising new strategies that could ultimately lead to the development of an efficacious vaccine.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"15 1","pages":"116055"},"PeriodicalIF":0.0,"publicationDate":"2026-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13010947/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147517150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterization of human immunodeficiency virus drug-resistance mutations among individuals with low-level-viremia in low-income and middle-income countries: A meta-analysis.","authors":"Ibrahim Ahmed El-Imam, Upendo Kayeke Chenya, Jackline Vicent Mbishi, Timothy Antipas Peter, Beatrice Kelvin Mpimo, Nicaise Ndembi, Hafidha Mhando Bakari, Mariam Salim Mbwana, Hassan Fredrick Fussi, Haji Mbwana Ally, Sanad Wael Dababneh, Habib Omari Ramadhani","doi":"10.5501/wjv.v15.i1.114375","DOIUrl":"10.5501/wjv.v15.i1.114375","url":null,"abstract":"<p><strong>Background: </strong>Low-level viremia (LLV) defined as [human immunodeficiency virus (HIV)-RNA 51-999 copies/mL] has been associated with an increased risk of drug resistance and treatment failure. Advances in next-generation sequencing enabled the detection of drug resistance mutations (DRM) among people with LLV. However, evidences remain limited in low-income and middle-income countries (LMIC) where surveillance is most needed to inform global epidemic control strategies.</p><p><strong>Aim: </strong>To determine the prevalence of HIV DRM among people living with HIV who have LLV in low- and middle-income countries.</p><p><strong>Methods: </strong>PubMed, Cochrane Library, and EMBASE were systematically searched for articles published between January 2015 and May 2025. Studies were included if they reported DRM among adolescents and/or adults with LLV in LMIC. Mutations were interpreted using Stanford University HIV Drug Resistance Database. Prevalence of DRM was computed as the proportion of resistance mutations among successfully sequenced samples. Pooled estimates of resistance mutation and 95%CI were calculated using random-effects models with stratified analyses comparing mutations by geographic location (Africa <i>vs</i> Asia).</p><p><strong>Results: </strong>Twenty studies including 7613 people with LLV were included. Of these, 5252 (73.9%) had their samples successfully sequenced. Eleven studies were from Africa and nine from Asia. Overall, the pooled prevalence of DRM was 50.4% (95%CI: 38.3-62.5) with a significantly higher prevalence observed among Africa studies compared to Asia's (58.0% <i>vs</i> 40.7%; <i>P</i> < 0.0001). The prevalence of mutations associated with nucleoside reverse transcriptase inhibitor and non-nucleoside reverse transcriptase inhibitor were 44.6% (95%CI: 34.8-54.4), and 50.9% (95%CI: 41.4-60.4) respectively and were significantly higher in Africa than in Asia. Protease inhibitor associated mutations were also common in Africa than in Asia (7.3% <i>vs</i> 4.1%; <i>P</i> < 0.001), though the overall prevalence remains low.</p><p><strong>Conclusion: </strong>Most individuals with LLV have resistance mutations and remain on a failed regimen over an extended period. Because resistance testing is not routinely performed in LMIC, lowering the viral failure threshold may improve timely switching to effective regimens, preserve treatment options, and reduce resistance accumulation in high HIV burden regions.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"15 1","pages":"114375"},"PeriodicalIF":0.0,"publicationDate":"2026-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13010904/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147517019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Viral hepatitis after liver transplantation: A brief overview.","authors":"Dibya Lochan Praharaj, Suprabhat Giri, Anil Chandra Anand, Bipadabhanjan Mallick, Preetam Nath, Saroj Kanta Sahu, Bramhadatta Pattnaik, Subrat Kumar Acharya, Yogesh Kumar Chawla","doi":"10.5501/wjv.v15.i1.114321","DOIUrl":"10.5501/wjv.v15.i1.114321","url":null,"abstract":"<p><p>Liver transplantation (LT) remains the only curative therapy in patients with end stage liver disease. With improvement in surgical techniques and immunosuppression protocols, both 1-year and 5-year survival have improved significantly. Similarly, recurrent hepatitis B virus and hepatitis C virus infection and consequent graft failure have become a thing of the past in the last few decades with the availability of highly effective nucleotide analogues and directly acting antivirals, respectively. However, infection with non-hepatotrophic viruses (<i>e.g.</i>, cytomegalovirus and Epstein-Barr virus) remains an important cause of graft failure and rejection, leading to increased morbidity and mortality. Chronic hepatitis E virus infection is also an emerging cause of viral hepatitis and liver failure in these patients. The key to successful management is early diagnosis and institution of appropriate antiviral therapy. In addition, the immunosuppression must be modified to maintain a balance between aggravating viral infection and rejection. The key purpose of this article is to provide an updated overview of various hepatotropic and non-hepatotropic viral hepatitis in patients undergoing LT. Risk factors, Clinical presentation, and diagnosis of viral hepatitis in LT settings will be discussed in detail. Recurrent hepatitis B virus and hepatitis C virus infection in transplanted grafts will also be described. Finally, the use of vaccination and immunoglobulin to prevent the development of these infections will also be described.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"15 1","pages":"114321"},"PeriodicalIF":0.0,"publicationDate":"2026-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13010926/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147517218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Seroprevalence and clinical profile of dengue infection among acute febrile patients at a rural tertiary care hospital.","authors":"Shree V Dhotre, Mangala P Ghatole, Pradnya S Dhotre, Virendra A Kashetty, Basavraj S Nagoba","doi":"10.5501/wjv.v15.i1.117079","DOIUrl":"10.5501/wjv.v15.i1.117079","url":null,"abstract":"<p><strong>Background: </strong>Dengue fever remains a major cause of acute febrile illness in India, particularly in rural areas where diagnostic facilities are limited. Early detection using point-of-care tests helps guide timely management and reduce unnecessary antibiotic use.</p><p><strong>Aim: </strong>To determine the seroprevalence and clinical profile of dengue infection among acute febrile patients attending a rural tertiary care hospital in Maharashtra.</p><p><strong>Methods: </strong>A prospective cross-sectional study was conducted at Ashwini Rural Medical College Hospital and Research Centre, Solapur from May to October 2025. A total of 320 consecutive patients presenting with acute fever of ≤ 7 days duration prior to hospital presentation were enrolled. Patients of all age groups were included. Serum samples were tested for dengue NS1 antigen and anti-dengue IgM and IgG antibodies using a commercial rapid test (Manufacturer: Meril diagnostics; Meriscreen dengue NS1 antigen and IgM + IgG antibodies). A 10% subset (<i>n</i> = 32) was tested by enzyme-linked immunosorbent assay (ELISA) for quality assurance. Patients were classified as recent dengue (NS1+ and/or IgM+), probable secondary infection (IgM+ IgG+), past exposure (IgG+ IgM-), or negative (NS1- IgM-). Clinical data and outcomes were recorded. Statistical analysis included <i>χ</i> ², Mann-Whitney <i>U</i>, and logistic regression (α = 0.05), adjusting for age, sex, platelet count, total leukocyte count, and presence of rash.</p><p><strong>Results: </strong>Overall, 28% (90/320) had evidence of recent dengue, while 35% (112/320) showed IgG positivity, and 10% (32/320) had probable secondary infection. Median platelet count was significantly lower in the recent dengue group [78000/mm³; interquartile range (IQR): 55000-110000] compared with non-dengue patients (210000/mm³; IQR: 160000-240000; <i>P</i> < 0.001). The most common symptoms were headache (68%), myalgia (61%), and retro-orbital pain (44%). Antibiotic use prior to testing was 60%; among those diagnosed with dengue, a relative 25% reduction in antibiotic prescriptions was observed following laboratory confirmation. Quality assurance analysis showed rapid test sensitivity of 92%, specificity of 95%, and Cohen's kappa of 0.85 <i>vs</i> ELISA. Logistic regression identified thrombocytopenia (< 100000/mm³) [adjust odds ratio (aOR) 5.2; 95%CI: 2.4-10.9] and rash (aOR 3.6; 95%CI: 1.8-7.0) as independent predictors of dengue positivity.</p><p><strong>Conclusion: </strong>A substantial proportion of acute febrile cases in this rural setting were due to dengue, highlighting the utility of NS1/IgM rapid tests for early diagnosis where molecular facilities are unavailable. Integrating rapid dengue testing into routine fever evaluation can improve case detection and rationalize antibiotic use.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"15 1","pages":"117079"},"PeriodicalIF":0.0,"publicationDate":"2026-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13010935/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147517159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Viral eye: Emerging insights into corneal and ocular surface viral infections.","authors":"Marco Zeppieri, Matteo Capobianco, Alessandro Avitabile, Federico Visalli, Cosimo Mazzotta, Mutali Musa, Rosa Giglio, Daniele Tognetto, Caterina Gagliano, Francesco Cappellani","doi":"10.5501/wjv.v14.i4.113449","DOIUrl":"10.5501/wjv.v14.i4.113449","url":null,"abstract":"<p><p>Viral infections of the ocular surface significantly contribute to morbidity and visual impairment globally. The herpes simplex virus (HSV), adenovirus, cytomegalovirus (CMV), and human papillomavirus (HPV) are predominant pathogens impacting the cornea and conjunctiva, resulting in recurrent illness, epidemic outbreaks, and virus-associated neoplasia. Progress in virology, immunology, and molecular diagnostics has enhanced comprehension of host-virus interactions and introduced novel therapeutic opportunities. A narrative literature review was performed utilizing PubMed, Scopus, and Web of Science, encompassing papers published from 2000 to 2025, with a specific focus on research from 2020 onwards. Eligible publications were peer-reviewed clinical and experimental investigations, together with reviews that focused on epidemiology, etiology, diagnostic methodologies, and therapeutic alternatives. Research indicates that HSV keratitis is the predominant infectious cause of corneal blindness in high-income nations, although adenovirus persists in instigating epidemics of keratoconjunctivitis in the absence of licensed antiviral treatments. CMV keratitis, previously confined to immunocompromised persons, is now acknowledged in immunocompetent patients as a causative agent of corneal endotheliitis. HPV is associated with ocular surface squamous neoplasia, especially in areas with elevated ultraviolet exposure and high human immunodeficiency virus prevalence. Innovative molecular diagnostics, innovative antiviral agents, immunomodulatory approaches, and immunization initiatives signify significant progress that could enhance preventative and therapeutic results.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"14 4","pages":"113449"},"PeriodicalIF":0.0,"publicationDate":"2025-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12754552/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145890556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cytomegalovirus reactivation risk after autologous hematopoietic stem cell transplantation: Results of a Tunisian study.","authors":"Mouna Louiza Ben Moussa, Yasmine Chelbi, Rachid Kharrat, Rabeb Berred, Raihane Ben Lakhal, Manel Hamdoun, Olfa Bahri","doi":"10.5501/wjv.v14.i4.115626","DOIUrl":"10.5501/wjv.v14.i4.115626","url":null,"abstract":"<p><strong>Background: </strong>Cytomegalovirus (CMV) reactivation is a potentially severe complication in immunocompromised patients, yet its incidence and impact in recipients of autologous hematopoietic stem cell transplantation (AHSCT) remain insufficiently documented.</p><p><strong>Aim: </strong>To assess the frequency, timing, and outcomes of CMV reactivation in patients undergoing AHSCT at Aziza Othmana Hospital.</p><p><strong>Methods: </strong>We conducted a retrospective descriptive study of all patients who underwent AHSCT between January 2022 and December 2024 and had at least one post-transplant plasma viral load (VL) assessment. CMV VL was quantified by real-time polymerase chain reaction using TaqMan probes (GeneProof^®) with a sensitivity threshold of 150 IU/mL.</p><p><strong>Results: </strong>Among 277 AHSCT recipients, 17 (6.1%) experienced CMV reactivation. Their median age was 43 years, with a sex ratio of 0.46 (male/female). Underlying diseases included large B-cell lymphoma (<i>n</i> = 5), multiple myeloma (<i>n</i> = 3), and Hodgkin's lymphoma (<i>n</i> = 4). The median time to reactivation was 26 days post-transplant (11 days after neutrophil recovery). Median peak VL was 1325 IU/mL (range: 150-641000 IU/mL). Six patients required antiviral therapy (median peak VL: 30150 IU/mL), while 11 had spontaneous resolution (median peak VL: 1320 IU/mL). Two patients died in the context of CMV reactivation.</p><p><strong>Conclusion: </strong>CMV reactivation occurs in a noteworthy proportion of AHSCT recipients and may lead to severe outcomes. Routine VL monitoring in the early post-transplant period is crucial, and preemptive therapy should be initiated once clinically relevant VL thresholds are reached to prevent progression to CMV disease and associated mortality.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"14 4","pages":"115626"},"PeriodicalIF":0.0,"publicationDate":"2025-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12754555/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145890563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Human immunodeficiency virus recency testing coverage and partner-notification-services among people-living with human immunodeficiency virus in low- and middle-income countries.","authors":"Ibrahim Ahmed El-Imam, Timothy Antipas Peter, Hassan Fredrick Fussi, Zuhura Mbwana Ally, Hafidha Mhando Bakari, Mariam Salim Mbwana, Upendo Kayeke Chenya, Beatrice Kelvin Mpimo, Haji Mbwana Ally, Habib Omari Ramadhani","doi":"10.5501/wjv.v14.i4.111810","DOIUrl":"10.5501/wjv.v14.i4.111810","url":null,"abstract":"<p><strong>Background: </strong>Human immunodeficiency virus (HIV) recency testing provides data that can be used to monitor the trend of new HIV infections. The effectiveness of using people identified with recent infection to identify partners with new HIV infection through partner notification services (PNS) is not well documented.</p><p><strong>Aim: </strong>To determine the pooled prevalence of recency testing coverage, recent infection, reclassification (recent to long-term infection) and PNS cascade among newly diagnosed people living with HIV.</p><p><strong>Methods: </strong>PubMed, Cochrane Library and Embase were searched for articles published between January 2018 and November 2024. Studies were included if they reported recency coverage and/or PNS among people newly diagnosed with HIV and used recent infection testing algorithm (RITA). Recency coverage was defined as proportion of people tested using rapid testing for recent infection (RTRI) among those newly diagnosed with HIV. RITA further classifies RTRI results using viral load results (≥ 1000 copies/mL <i>vs</i> < 1000 copies/mL) to confirm recency status. For studies with PNS, we evaluated the cascade: Number of partners elicited, successfully contacted, eligible for HIV testing, tested and HIV diagnosis. PNS effectiveness was measured by proportion of new HIV diagnoses from tested partners. Using random effects models, we computed the pooled estimate of recency outcomes and 95% confidence intervals (CIs).</p><p><strong>Results: </strong>Twenty-five studies from 17-low- and middle-income countries were included. Of 276315 newly diagnosed people living with HIV, 79864 underwent RTRI with an overall pooled recency coverage of 87% (95%CI: 67-96). The pooled prevalence of RTRI and RITA recency were 12% (95%CI: 9-16) and 7% (95%CI: 4-10), respectively. Pooled prevalence of RTRI reclassification was 34% (95%CI: 22-49). Of the recent cases who agreed to PNS, 253 partners were elicited with an estimated elicitation ratio of 1:1.6. Among partners elicited, 99% were successfully contacted, 75% were eligible for testing, 68% tested for HIV, and 15% were diagnosed with HIV.</p><p><strong>Conclusion: </strong>High recency testing coverage among newly diagnosed individuals demonstrates the feasibility of monitoring new HIV infections in LMIC. While PNS yielded moderate HIV diagnoses, its targeted approach remains a critical strategy for identifying undiagnosed cases.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"14 4","pages":"111810"},"PeriodicalIF":0.0,"publicationDate":"2025-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12754530/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145890596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atypical presentation of pediatric acute hepatitis A: Is the situation alarming?","authors":"Rubaiyat Alam","doi":"10.5501/wjv.v14.i4.114174","DOIUrl":"10.5501/wjv.v14.i4.114174","url":null,"abstract":"<p><p>Hepatitis A virus (HAV) infection remains a significant public health concern in many developing countries. The annual incidence of HAV infection is 1.5 million, though this figure may be underestimated owing to the infection's asymptomatic nature and the presence of milder disease variants. The clinical spectrum of HAV infection now ranges from asymptomatic infection to fulminant hepatitis. Despite the availability of safe and highly effective vaccines, HAV infections remain a major contributor to acute viral hepatitis worldwide.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"14 4","pages":"114174"},"PeriodicalIF":0.0,"publicationDate":"2025-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12754536/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145890613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of three pediatric studies investigating acute hepatitis of unknown etiology.","authors":"Haruki Komatsu","doi":"10.5501/wjv.v14.i4.110435","DOIUrl":"10.5501/wjv.v14.i4.110435","url":null,"abstract":"<p><p>Between 2021 and 2023, approximately 400 pediatric cases of acute hepatitis of unknown etiology (AHUE) were reported in European countries and the United States. In 2023, three pediatric studies revealed that adeno-associated virus serotype 2 (AAV-2) infection was associated with AHUE. This article presents a summary and comparison of the results of metagenomic sequencing, viral whole-genome sequencing, virus-specific real-time polymerase chain reaction (PCR) and histological analysis of the liver, all of which were among the common investigative methods used in the three pediatric studies. All three pediatric studies revealed 80% or greater rates of positivity for AAV-2 in cases of AHUE according to metagenomic sequencing. Moreover, on the basis of PCR results, two studies revealed high AAV-2 positivity rates (96.4% and 81.2%) among cases of AHUE. These findings suggest that AAV-2 is a pathogen in AHUE. Coinfection with AAV-2 and one or more helper viruses (human adenovirus, human herpesvirus 6B, Epstein-Barr virus, <i>etc.</i>), high viral loads of AAV-2 in blood, anti-AAV-2 IgM and human leukocyte antigen typing could be candidate diagnostic criteria for AHUE. AAV-2 infection should be incorporated into clinical guidelines for the management of acute liver failure. Cidofovir can be administered if coinfection with AAV-2 and HAdV is detected.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"14 4","pages":"110435"},"PeriodicalIF":0.0,"publicationDate":"2025-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12754543/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145890598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disclosure and peer support in prevention of mother-to-child transmission of human immunodeficiency virus: Evidence from Rwanda.","authors":"Saurav Basu","doi":"10.5501/wjv.v14.i4.111700","DOIUrl":"10.5501/wjv.v14.i4.111700","url":null,"abstract":"<p><p>This retrospective cohort study from Rwanda demonstrated the likelihood of maternal disclosure and peer support in preventing mother-to-child human immunodeficiency virus (HIV) transmission. High sustained maternal viral load suppression (91.0%) and exceptional infant testing uptake (100% at 6 weeks) correlated with a low 0.7% infant HIV incidence. To eliminate mother-to-child transmission of HIV, effective strategies must engage male partners in disclosure, reduce stigma, improve health literacy, and provide structural peer-support for enhancing adherence and mental health.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"14 4","pages":"111700"},"PeriodicalIF":0.0,"publicationDate":"2025-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12754539/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145890608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}